作者：陈余文，王悦，李冰清，万少枝，李册兴，李文倩，孙培媛，吕建峰

单位：

443000湖北省宜昌市，三峡大学心脑血管疾病研究所 三峡大学附属仁和医院心血管内科

Units：

Institute of Cardiovascular and Cerebrovascular Diseases, China Three Gorges University/Internal Medicine-CardiovascularDepartment, Affiliated Renhe Hospital of China Three Gorges University, Yichang 443000, China

关键词：

心力衰竭；氧化应激；钠-葡萄糖共转运蛋白2抑制剂；药理作用机制；综述

Keywords：

Heart failure; Oxidative stress; Sodium-glucose cotransporter 2 inhibitor; Pharmacological mechanisms ofaction; Review

CLC：

R 541.6　R 977.15　

DOI：

10.12114/j.issn.1008-5971.2022.00.250

Funds：

湖北省卫生健康委员会科研项目（WJ2021F061）

摘要：

钠-葡萄糖共转运蛋白2抑制剂（SGLT2i）是一种新型降糖药。在《2021 ESC心力衰竭指南》中，SGLT2i被列为心力衰竭的一线推荐药物，其能降低血糖、促进尿钠排泄、抗氧化、抗炎、抗细胞凋亡等。心力衰竭患者心肌细胞处于高氧化应激状态，而SGLT2i能减轻氧化应激并发挥心脏保护作用。笔者通过分析相关文献发现，SGLT2i抗氧化应激的机制可能为改善线粒体功能、调节抗氧化酶活性、抑制炎症因子表达、抑制肾素-血管紧张素系统（RAS）激活、降血糖。

Abstract：

　Sodium-glucose cotransporter 2 inhibitor (SGLT2i) is a new type of hypoglycemic agent. In the 2021 ESCHeart Failure Guidelines , SGLT2i is listed as the first-line recommended drug for heart failure, which can reduce blood glucose,promote urinary sodium excretion, antioxidant, anti-inflammatory, anti apoptosis, etc. Myocardial cells in patients with heartfailure are in a state of high oxidative stress, and SGLT2i can reduce oxidative stress and play a role in cardiac protection. Byanalyzing the relevant literature, the author finds that the antioxidant stress mechanism of SGLT2i may be to improve mitochondrialfunction, regulate antioxidant enzyme activity, inhibit inflammatory factors, inhibit expression of renin-angiotensin system (RAS)activation, and reduce blood glucose.

ReferenceList：